Mensia Technologies SA   Report issue

For profit Phase 2
Founded: Paris France (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2016
NCT02778360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Mensia Technologies

Active Ingredients

Drugs in Phase 2 Trials (1)

methylphenidate (ritalin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Hyperkinesis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1